← Russell 3000 cross-section

TFX TELEFLEX INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$5.8bn
Revenue TTM
$2.6bn
Net income TTM
$-1.0bn
Free cash flow
$91m
Composite score
36.5
Sector rank
#983

Valuation

P / E
EV / EBITDA
EV / sales
3.2
FCF yield
1.55%
Earnings yield vs 10-yr
-22.38pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-39.7%
EBITDA margin
-5.9%
ROE
-35.5%
ROIC
-5.6%
Revenue growth
-3.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel. In addition to increases and decreases in the per unit selling prices of our products to our customers, our discussion of the impact of product price increases and decreases also reflects the impact on the pricing of our products resulting from the elimination of the distributor, either through acquisition or termination of the distributor, from the sales channel. …TELEFLEX INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →